RYTM - RHYTHM PHARMACEUTICALS, INC.

84.92
-2.800   -3.297%

Share volume: 503,469
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$87.72
-2.80
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 2%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.44%
1 Month
3.63%
3 Months
-17.21%
6 Months
-18.13%
1 Year
45.04%
2 Year
124.87%
Key data
Stock price
$84.92
P/E Ratio 
0.00
DAY RANGE
$83.82 - $87.72
EPS 
-$3.11
52 WEEK RANGE
$55.31 - $122.20
52 WEEK CHANGE
$48.10
MARKET CAP 
7.143 B
YIELD 
N/A
SHARES OUTSTANDING 
68.285 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
1.78
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$581,345
AVERAGE 30 VOLUME 
$843,604
Company detail
CEO: David P. Meeker
Region: US
Website: rhythmtx.com
Employees: 140
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Rhythm Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency.

Recent news